Status: Recruiting
A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus
This study will evaluate the safety and efficacy of GIA632 in participants with moderate to severe cutaneous lichen planus (cLP).
Participants needed: 259
Trial details
Phase: Phase 2Age: 18-99Biological sex: AllType: InterventionalSponsor: Novartis PharmaceuticalsUpdated: Oct 13, 2026Locations: 21
Eligibility criteria
Male or female (as assigned at birth) participants ≥ 18 years of age at the time... [+6]
Individuals unable or unwilling to follow the study procedures, handle the elect... [+4]